Related Experiment Videos
[Hysterosalpingography using iotrolan--a new contrast medium]
H J Jensen1, H Dons-Jensen, K M Kamal
1Abteilung für Radiologie, Hjörring Krankenhaus Dänemark.
Aktuelle Radiologie
|September 1, 1993
Summary
Iotrolan, a new contrast agent for hysterosalpingography, shows promising fertility rates compared to water-soluble media. However, its fertility outcomes are lower than Lipiodol, with similar side effects to Lipiodol.
Area of Science:
- Reproductive Medicine
- Radiology
- Gynecologic Imaging
Background:
- Hysterosalpingography (HSG) is crucial for evaluating female infertility.
- The choice of contrast medium impacts HSG outcomes, including fertility and side effects.
- Iotrolan is a novel contrast agent evaluated for HSG procedures.
Purpose of the Study:
- To investigate the efficacy and safety of iotrolan as a contrast medium for hysterosalpingography.
- To compare fertility rates and side effects associated with iotrolan versus other contrast agents.
- To assess the clinical utility of iotrolan in a series of 108 patients.
Main Methods:
- A series of 108 consecutive patients undergoing hysterosalpingography.
- Registration of fertility rates and patient-reported side effects.
- Comparison of iotrolan with other water-soluble contrast media and Lipiodol.
Main Results:
- Hysterosalpingography with iotrolan resulted in higher fertility rates than other water-soluble contrast media.
- Fertility rates with iotrolan were lower compared to Lipiodol.
- Side effect profiles for iotrolan and Lipiodol were similar regarding abdominal pain and vaginal bleeding, both being lower than with other water-soluble media.
Conclusions:
- Iotrolan presents a potentially favorable option for hysterosalpingography regarding fertility and side effects.
- Further prospective, randomized studies are recommended to definitively clarify the comparative efficacy and safety of iotrolan.
- The findings suggest iotrolan may offer an alternative with a manageable side effect profile for infertility investigations.